Clinical Trial Update: Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Ontak (denileukin diftitox) in patients with systemic mastocytosis and leukemia. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Systemic Mastocytosis

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Systemic Mastocytosis | Phase 2 | Status: COMPLETED